Thomas S. Marshall

616 total citations
20 papers, 451 citations indexed

About

Thomas S. Marshall is a scholar working on Epidemiology, Rheumatology and Urology. According to data from OpenAlex, Thomas S. Marshall has authored 20 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 5 papers in Rheumatology and 4 papers in Urology. Recurrent topics in Thomas S. Marshall's work include Pelvic floor disorders treatments (5 papers), Urinary Tract Infections Management (5 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Thomas S. Marshall is often cited by papers focused on Pelvic floor disorders treatments (5 papers), Urinary Tract Infections Management (5 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Thomas S. Marshall collaborates with scholars based in United States, Germany and Japan. Thomas S. Marshall's co-authors include Kavita Sail, Angelo Antonini, Leah Kleinman, Koray Onuk, Per Odin, Anne Skalicky, A. Jon Stoessl, Michael D. Vardy, Wanzhong He and John D. Wegenke and has published in prestigious journals such as Blood, Clinical Oral Implants Research and Journal of Prosthetic Dentistry.

In The Last Decade

Thomas S. Marshall

19 papers receiving 439 citations

Peers

Thomas S. Marshall

NEURO

UROLO

EPIDE

RHEUM

B. Nicolas France

Reza Salman Roghani Iran

Necmettin Yıldız Türkiye

S. Robineau France

Arun Alexander India

Konçuy Sivrioğlu Türkiye

John Joseph United States

A C F Hui China

Paul E. Kaplan United States

H. Kurth France

B. Nicolas France

Thomas S. Marshall

161 ×0.7

NEURO

134 ×1.3

UROLO

83 ×0.8

EPIDE

116 ×1.2

RHEUM

17 ×0.3

Citations per year, relative to Thomas S. Marshall Thomas S. Marshall (= 1×) peers B. Nicolas

Countries citing papers authored by Thomas S. Marshall

Since Specialization

Citations

This map shows the geographic impact of Thomas S. Marshall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas S. Marshall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas S. Marshall more than expected).

Fields of papers citing papers by Thomas S. Marshall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas S. Marshall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas S. Marshall. The network helps show where Thomas S. Marshall may publish in the future.

Co-authorship network of co-authors of Thomas S. Marshall

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas S. Marshall. A scholar is included among the top collaborators of Thomas S. Marshall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas S. Marshall. Thomas S. Marshall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Delforge, Michel, Krina K. Patel, Devender Dhanda, et al.. (2024). Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. The Lancet Haematology. 11(3). e216–e227. 17 indexed citations

Delforge, Michel, Krina K. Patel, Devender Dhanda, et al.. (2023). Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial. Blood. 142(Supplement 1). 96–96. 2 indexed citations

Lee, Hans C., Sundar Jagannath, Devender Dhanda, et al.. (2023). Clinical Outcomes in Real-World Patients (RW) with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): A Retrospective Study Using Electronic Health Records from Flatiron Health and COTA Vantage Databases. Blood. 142(Supplement 1). 3775–3775.

Sullivan, Jeffrey, Tiffany Shih, Yash J. Jalundhwala, et al.. (2020). The Social Value of Improvement in Activities of Daily Living among the Advanced Parkinson’s Disease Population. Forum for Health Economics & Policy. 23(2). 1–23. 2 indexed citations

Shih, Tiffany, Kavita Sail, Yash J. Jalundhwala, et al.. (2019). The effect of functional status impairment on nursing home admission risk among patients with advanced Parkinson’s disease. Journal of Medical Economics. 23(3). 297–307. 8 indexed citations

Antonini, Angelo, A. Jon Stoessl, Leah Kleinman, et al.. (2018). Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Current Medical Research and Opinion. 34(12). 2063–2073. 172 indexed citations

Lowin, Julia, et al.. (2017). The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson’s disease. Journal of Medical Economics. 20(11). 1207–1215. 28 indexed citations

Pålhagen, Sven, Olof Sydow, Anders Johansson, et al.. (2016). Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson’s disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism & Related Disorders. 29. 17–23. 43 indexed citations

Nuijten, Mark, et al.. (2015). Health Economic Evaluation of Paricalcitol® Versus Cincalcet + Calcitriol (Oral) in Italy. Clinical Drug Investigation. 35(4). 229–238. 3 indexed citations

10.

Sharma, Amit, et al.. (2013). Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA. Clinical Drug Investigation. 34(2). 107–115. 11 indexed citations

11.

Wu, Ning, et al.. (2013). Antimuscarinic use among individuals with urinary incontinence who reside in long-term care facilities. International Urology and Nephrology. 46(1). 285–296. 2 indexed citations

12.

Ketteler, Markus, et al.. (2013). Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients. Journal of Medical Economics. 16(9). 1129–1136. 5 indexed citations

13.

Marshall, Thomas S., et al.. (2012). Supplementing retention through crown/preparation modification: An in vitro study. Journal of Prosthetic Dentistry. 107(3). 186–190. 11 indexed citations

14.

Notte, Sherilyn M., Thomas S. Marshall, Misun Lee, et al.. (2012). Content validity and test-retest reliability of patient perception of intensity of urgency scale (PPIUS) for overactive bladder. BMC Urology. 12(1). 26–26. 40 indexed citations

15.

Crosby, Ross D., Susan D. Mathias, & Thomas S. Marshall. (2011). Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. International Journal of Clinical Practice. 65(2). 211–218. 8 indexed citations

16.

Taneja, Charu, Richard J. Antaya, Ariel Berger, et al.. (2010). Cost-effectiveness of tacrolimus ointment versus pimecrolimus cream in adults with atopic dermatitis.. PubMed. 9(4). 372–6. 9 indexed citations

17.

Vardy, Michael D., et al.. (2009). Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. International Journal of Clinical Practice. 63(12). 1702–1714. 46 indexed citations

18.

Cisternas, Miriam G., Aimee J. Foreman, Thomas S. Marshall, et al.. (2009). Estimating the prevalence and economic burden of overactive bladder among Medicare beneficiaries prior to Medicare Part D coverage. Current Medical Research and Opinion. 25(4). 911–919. 23 indexed citations

19.

Marshall, Thomas S., J.S. McCombs, & Dana Stafkey-Mailey. (2008). Impact of Patient Selection Criteria and Treatment History on Comparisons of Alternative Therapies: A Case Study of Atypical Antipsychotics. Value in Health. 12(4). 473–480. 4 indexed citations

20.

Marshall, Thomas S., Zvi Schwartz, L.D. Swain, et al.. (1991). Matrix vesicle enzyme activity in endosteal bone following implantation of bonding and non.‐bonding implant materials. Clinical Oral Implants Research. 2(3). 112–120. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact